Evidence map›Paper›PMID 36780057›Full record

ArticleMolecular biotechnology2023

Anticancer and Biological Effects of Some Natural Compounds and Theoretical Investigation of them Against RdRP of SARS-COV-2: In Silico and In Vitro Studies.

Jing Zhang, Jingyu Feng, Yang Li, Jiguo Wang, Panyan Mo, Changguo Luo

Abstract read
In one paragraph

Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jing ZhangDepartment of Oncology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, 518000, China.
Jingyu FengDepartment of Oncology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, 518000, China.
Yang LiDepartment of Oncology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, 518000, China.
Jiguo WangDepartment of Oncology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, 518000, China.
Panyan MoDepartment of Oncology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, 518000, China.
Changguo LuoDepartment of Oncology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, 518000, China. zhangjingtongxun@163.com.ORCID http://orcid.org/0000-0002-8520-8657

Funding

Shenzhen Baoan District Science and Technology Innovation Bureau 2021JD148
6 · The paper itself

Abstract

In this study, Skullcapflavone I and Skullcapflavone II molecules showed good inhibitory activities against α-glucosidase and sorbitol dehydrogenase enzymes with IC50 values of 102.66 ± 8.43 and 95.04 ± 11.52 nM for α-glucosidase and 38.42 ± 3.82 and 28.81 ± 3.26 µM for sorbitol dehydrogenase. The chemical activities of Skullcapflavone I and Skullcapflavone II against α-glucosidase and sorbitol dehydrogenase were assessed by conducting the molecular docking study. The anticancer activities of the compounds were examined against SW-626, SK-OV-3, OVCAR3, and Caov-3 cell lines. The chemical activities of Skullcapflavone I and Skullcapflavone II against some of the expressed surface receptor proteins (estrogen receptor, EGFR, androgen receptor, and GnRH receptor) in the mentioned cell lines were investigated using in silico calculations. Moreover, the activity of the compounds against RNA polymerase of SARS-COVE-2 was also assessed using the molecular modeling study. These compounds created strong contacts with the enzymes and receptors. The considerable binding affinity of the compounds to the enzymes and proteins showed their ability as inhibitors. Furthermore, even at modest dosages, these substances markedly reduced the viability of ovarian cancer cells. Additionally, the viability of ovarian cancer cells was significantly decreased by a 300 μM dosage of all compounds. Antiovarian cancer results of Skullcapflavone I on SK-OV-3, SW-626, OVCAR3, and Caov-3 were 63.14, 1.55, 19.42, and 52.04 µM, respectively. Also, cytotoxicity results of Skullcapflavone II on SK-OV-3, SW-626, OVCAR3, and Caov-3 were 5.18, 21.44, 33.87, and 72.66 µM, respectively.

Indexed as

COVID-19Ovarian Neoplasmsalpha-GlucosidasesApoptosisCell Line, TumorFemaleHumansL-Iditol 2-DehydrogenaseMolecular Docking SimulationRNA-Dependent RNA PolymeraseSARS-CoV-2alpha-GlucosidasesL-Iditol 2-DehydrogenaseRNA-Dependent RNA PolymeraseCytotoxicityIn silico studyNatural compoundsSorbitol dehydrogenaseα-glucosidase

Identifiers

PMID36780057
PMCPMC9923641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.